NDA Clinical Briefing Package Submitted to the US FDA
Telix Pharmaceuticals announces that it has submitted a complete clinical briefing package to the US FDA for its first product…
Read moreNews & Views
Telix Pharmaceuticals announces that it has submitted a complete clinical briefing package to the US FDA for its first product…
Read moreTelix Pharmaceuticals Limited announces that it has submitted a Phase 3 IND application to the FDA for…
Read moreTelix Pharmaceuticals has released an update on the progress of its TLX101 product in the treatment of glioblastoma…
Read moreNews,
Telix Pharmaceuticals announces University of Melbourne collaboration with Telix receives Cancer Australia research…
Read moreTelix Pharmaceuticals Limited and French company ATONCO S.A.S are pleased to announce they have entered into a Licence and Development Agreement that will enable ATONCO to investigate the use of Telix’s…
Read moreTelix Pharmaceuticals Limited is pleased to announce that Group CEO, Dr. Christian Behrenbruch, presented at Jefferies 2019 London Healthcare Conference….
Read moreDr. Christian Behrenbruch, CEO of Telix Pharmaceuticals Limited will speak at Jefferies 2019 London Healthcare Conference. This year marks the 10th anniversary of now the largest healthcare-dedicated conference in Europe,…
Read moreTelix Pharmaceuticals Limited is pleased to release a Clinical Trial Program Update for Q3,…
Read moreTelix Pharmaceuticals Limited has today announced that Telix and AusHealth have entered into a collaboration and technology licensing agreement for a novel Molecularly Targeted Radiation (MTR) platform called APOMAB® intended for the…
Read moreTelix is pleased to announce that it has entered into a conditional purchase agreement with Eckert & Ziegler Strahlen and Medizintechnik Aktiengesellschaft to acquire a licensed radiopharmaceutical production facility in Seneffe,…
Read more